Guangdong Hybribio BiotechLtd Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jianyu Wang

Chief Executive Officer (CEO)

CN¥6.1m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	6.7yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

May 03

CEO

Jianyu Wang (62 yo)

1.8yrs

Permanencia

CN¥6,109,300

Compensación

Ms. Jianyu Wang is the General Manager at Guangdong Hybribio Biotech Co.,Ltd. since August 31, 2022 and was its Executive Deputy General Manager until August 31, 2022. She has been Director at Guangdong Hy...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jianyu Wang	GM & Director	1.8yrs	CN¥6.11m	sin datos
Qinghui Li	Finance Director	10.1yrs	CN¥953.10k	0.0071% CN¥ 296.8k
Longxu Xie	Deputy GM & Director	13.7yrs	CN¥1.46m	0.058% CN¥ 2.4m
Zhisheng Guan	Executive Deputy GM & Non Independent Director	no data	CN¥9.39m	0.57% CN¥ 23.7m
Yi Chen	Deputy GM & Board Secretary	no data	CN¥918.20k	0.013% CN¥ 527.9k
Danrong Weng	Deputy General Manager	3.3yrs	CN¥1.03m	0.0055% CN¥ 230.7k

6.7yrs

Permanencia media

48.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300639 es experimentado (6.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jianyu Wang	GM & Director	7.7yrs	CN¥6.11m	sin datos
Longxu Xie	Deputy GM & Director	3.6yrs	CN¥1.46m	0.058% CN¥ 2.4m
Zhisheng Guan	Executive Deputy GM & Non Independent Director	13.7yrs	CN¥9.39m	0.57% CN¥ 23.7m
Meilan Qiu	Supervisor	6.9yrs	sin datos	sin datos
Weixiong Huang	Vice Chairman of the Board	13.7yrs	CN¥300.00k	sin datos
Xiaoyan Yang	Director	13.7yrs	CN¥120.00k	sin datos
Qiaozhong Guan	Chairman of the Board	13.7yrs	CN¥3.74m	sin datos
Wanjian Xu	Employee Representative Supervisor	10.8yrs	sin datos	sin datos
Ruijun Ma	Chairman of the Supervisory Board	4.7yrs	sin datos	sin datos
Youlin Qiao	Independent Director	1.8yrs	CN¥40.00k	sin datos
Chunxue Yang	Independent Director	1.8yrs	CN¥40.00k	sin datos
Yingshi Chen	Independent Director	1.8yrs	CN¥40.00k	sin datos

7.3yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 300639 se considera experimentada (7.2 años de antigüedad promedio).

Guangdong Hybribio BiotechLtd Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Less than half of directors are independent

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Recent updates

There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, May 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 24% overvalued

Guangdong Hybribio Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorates as stock falls 16%

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: EPS: CN¥0.076 (vs CN¥0.78 in 3Q 2022)

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.088 (vs CN¥0.73 in 2Q 2022)

Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. (SZSE:300639) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on October 10, 2022.

Third quarter 2022 earnings released: EPS: CN¥1.17 (vs CN¥0.59 in 3Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Announces Director Appointments

Second quarter 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.50 in 2Q 2021)

Less than half of directors are independent

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2021, Payable on April 29, 2022

Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd., Annual General Meeting, Apr 15, 2022

Guangdong Hybribio Biotech Co.,Ltd. Announces Final Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Now 22% undervalued

Investor sentiment improved over the past week

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.88 (vs CN¥0.54 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.75 (vs CN¥0.43 in 2Q 2020)

Investor sentiment improved over the past week

Guangdong Hybribio Biotech Co.,Ltd. Declares Dividend Implementation of A Shares for the Year 2020, Payable on May 28, 2021

Guangdong Hybribio Biotech Co.,Ltd. Approves Profit Distribution for 2020

First quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.09 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.70 in FY 2019)

New 90-day low: CN¥32.33

Guangdong Hybribio Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 15, 2021

New 90-day low: CN¥33.91

Investor sentiment deteriorated over the past week

New 90-day low: CN¥42.94

Third quarter earnings released

Third quarter earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 23, 2020

First half earnings released

Guangdong Hybribio Biotech Co.,Ltd. to Report First Half, 2020 Results on Aug 15, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad